title: [Probiotics in the treatment of functional intestinal diseases].
abstract: to evaluate the clinical effectiveness of biocomplexes "Normoflorin L, B" in the treatment of functional bowel disease with constipation syndrome. The study involved 30 patients with functional bowel disease (Rome criteria III, 2006), with irritable bowel syndrome with predominance of constipatio--16 people with functional constipation--14 people. The criteria of efficacy were: the dynamics of clinical symptoms, bacteriological examination of feces before and after treatment, intestinal transit time of Activated Charcoa- "carbolen" test the definition of short-chain fatty acids (SFA) in the feces by gas-liquid chromatography before and after treatment. The results of the study. In Normoflorin therapy there comes normalization of intestinal motor activity; positive changes in colon ecosystem, consisting of changes of methabolic activity of colonic microflora and its generic composition, normalization of anaerobic-aerobic relations, restoration of intracavitary redox potential of the luminal environment; eliminating the symptoms of intestinal dyspepsia (rumbling, flatulence). Bio-complexes Normofloriny are characterized by good tolerability and safety. The positive effect of "aftereffect" of drugs persists for at least 2 weeks. These data allow us to recommend the use of bio-complexes Normofloriny in treatment of functional bowel disease. These data allow to recommend the use of bio-complexes Normofloriny in treatment of functional bowel disease.
authors: M D
authors: MD
authors: Ardatskaia
authors: O N
authors: ON
authors: Minushkin
mesh_terms: D000293:Adolescent; D000328:Adult; D003248:Constipation / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D005232:Fatty Acids, Volatile / Q000032:analysis; D005243:Feces / Q000737:chemistry / Q000382:microbiology; D005260:Female; D005772:Gastrointestinal Transit / Q000187:drug effects; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005232:Fatty Acids, Volatile